View Older Stories View More Recent Stories
-
Citi Adjusts Catalyst Watch List
-
Truist Securities Upgrades Tandem Diabetes Care (TNDM) to Buy
-
Piper Sandler Upgrades Tandem Diabetes Care (TNDM) to Overweight
-
Tandem Diabetes expands Mobi insulin pump to Android smartphones
-
Tandem Diabetes Care (TNDM) PT Raised to $27 at Truist Securities
-
Lake Street Capital Markets Upgrades Tandem Diabetes Care (TNDM) to Buy, 'Intentional Shift To The Pharmacy A Welcomed Transition'
-
Tandem Diabetes Care (TNDM) PT Raised to $27 at Truist Securities
-
Tandem Diabetes Care (TNDM) PT Raised to $22 at Stifel Following Q4 Revenue Beat
-
Tandem Diabetes Care (TNDM) PT Raised at Piper Sandler Following 'More Positive Results'
-
Tandem Diabetes Care (TNDM) PT Raised to $22 at Mizuho
-
BofA Securities Upgrades Tandem Diabetes Care (TNDM) to Neutral
-
Tandem Diabetes (TNDM) Tops Q4 EPS by 8c; offers guidance
-
Bernstein Highlights Top U.S. Medtech 2026 Picks: 'Sector Poised For a Rebound'
-
Baird Upgrades Tandem Diabetes Care (TNDM) to Outperform
-
Bernstein Shares Takeaways From the 5th Annual Diabetes Disruptor Conference
-
Citi Adds 90-Day Catalyst Watch on Tandem Diabetes Care (TNDM)
-
Tandem Diabetes gets FDA clearance for Android app
-
Tandem Diabetes Care (TNDM) PT Raised to $16 at Stifel
-
Tandem Diabetes (TNDM) Tops Q3 EPS by 1c ; Offers Guidance
-
Stifel Resumes Tandem Diabetes Care (TNDM) at Hold
-
Tandem t:slim X2 insulin pump gains clearance for Lyumjev insulin
-
Tandem Diabetes Care study shows insulin delivery system benefits type 2 patients
-
Oppenheimer Assumes Tandem Diabetes Care (TNDM) at Outperform
-
Citi Upgrades Tandem Diabetes Care (TNDM) to Neutral
-
Tandem Diabetes Care (TNDM) PT Lowered to $22 at CFRA, 'we anticipate a $10 million headwind in 2025'
-
Lake Street Capital Markets Assumes Tandem Diabetes Care (TNDM) at Hold
-
Tandem Diabetes Care (TNDM) PT Lowered at TD Cowen Amid US Guidance Cut
-
Tandem Diabetes Care (TNDM) PT Lowered to $51 at Barclays
-
Piper Sandler Downgrades Tandem Diabetes Care (TNDM) to Neutral
-
Tandem Diabetes (TNDM) Misses Q2 EPS by 38c, provides guidance
-
Piper Sandler's Key MedTech Takeaways From ADA 2025
-
4 MedTech stocks to buy in 2025: Citi
-
Tandem Diabetes (TNDM) buyer of of 2200 contracts of August 23 calls
-
Truist Securities Starts Tandem Diabetes Care (TNDM) at Hold
-
Tandem Diabetes (TNDM) partners with Abbott (ABT) for integration
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
Tandem Diabetes Care (TNDM) PT Raised to $59 at Canaccord Genuity
-
Tandem Diabetes (TNDM) Misses Q1 EPS by 137c, provides guidance
-
Mizuho Starts Tandem Diabetes Care (TNDM) at Neutral
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Stifel Reiterates Buy Rating on Tandem Diabetes Care (TNDM)
-
Tandem Diabetes (TNDM) Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
-
Morgan Stanley Downgrades Tandem Diabetes Care (TNDM) to Equalweight
-
Citi Downgrades Tandem Diabetes Care (TNDM) to Neutral
-
Bernstein SocGen Group Downgrades Tandem Diabetes Care (TNDM) to Market Perform
-
Bernstein SocGen Group Downgrades Tandem Diabetes Care (TNDM) to Market Perform
-
Tandem Diabetes Care (TNDM) PT Lowered to $35 at Citi
-
Tandem Diabetes (TNDM) Tops Q4 EPS by 22c ; Offers Guidance
-
Canaccord Genuity Reiterates Buy Rating on Tandem Diabetes Care (TNDM) following Type 2 diabetes FDA clearance
-
Tandem Diabetes (TNDM) Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes

